VENATORX

Venatorx Pharmaceuticals is a private company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company name, Venatorx (ven-a-TOREX), derives from the Latin word "venator", meaning ‘hunter' and "Rx", the medical symbol for prescription drugs. The hunt for new innovative medicines is the core mission of the company. Founded in 2010, Venatorx has built a world-class in-house research and development organization. Venatorx's lead asset, cefepime-taniborbactam, is an investigational antibiotic that has completed a Phase 3 study (NCT03840148) in adults with complicated urinary tract infections (cUTI), including pyelonephritis. A New Drug Application for U.S. marketing authorization is currently under FDA review. In 2022, BARDA awarded a Project Bioshield contract of up to $318 million to Venatorx for development and procurement of cefepime-taniborbactam for the treatment..

Also known as: Venatorx Pharmaceuticals, Venatorx Pharmaceuticals, Inc.

Primary location: Malvern United States